Cargando…
Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
OBJECTIVE: Recent studies have proven the favorable effects of angiotensin receptor blockers (ARBs) on cardiovascular and renal disorders. However, determinants of the response to ARBs remain unclear. We substantiated the hypothesis that genetic variants of the renin-angiotensin system (RAS) have si...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713645/ https://www.ncbi.nlm.nih.gov/pubmed/19509012 http://dx.doi.org/10.2337/dc09-0348 |
_version_ | 1782169594747682816 |
---|---|
author | Konoshita, Tadashi Kato, Norihiro Fuchs, Sébastien Mizuno, Shinichi Aoyama, Chikako Motomura, Makoto Makino, Yasukazu Wakahara, Shigeyuki Inoki, Isao Miyamori, Isamu Pinet, Florence |
author_facet | Konoshita, Tadashi Kato, Norihiro Fuchs, Sébastien Mizuno, Shinichi Aoyama, Chikako Motomura, Makoto Makino, Yasukazu Wakahara, Shigeyuki Inoki, Isao Miyamori, Isamu Pinet, Florence |
author_sort | Konoshita, Tadashi |
collection | PubMed |
description | OBJECTIVE: Recent studies have proven the favorable effects of angiotensin receptor blockers (ARBs) on cardiovascular and renal disorders. However, determinants of the response to ARBs remain unclear. We substantiated the hypothesis that genetic variants of the renin-angiotensin system (RAS) have significant impacts on the response to ARBs. RESEARCH DESIGN AND METHODS: Subjects comprised 231 consecutively enrolled hypertensive individuals including 45 type 2 diabetic subjects. Five genetic variants of the RAS, i.e., renin (REN) C-5312T, ACE insertion/deletion, angiotensinogen M235T, angiotensin II type 1 receptor A1166C, and angiotensin II type 2 receptor C3123A were assayed by PCR and restriction fragment-length polymorphism. A dose of 40–160 mg/day of valsartan was administered for 3 months as a monotherapy. RESULTS: Changes in diastolic blood pressure significantly differed between genotypes of REN C-5312T: 10.7-mmHg reduction (from 95.9 ± 12.9 to 85.2 ± 11.4) in CC versus 7.0-mmHg reduction (from 94.7 ± 14.0 to 87.7 ± 12.6) in CT/TT (P = 0.02 for interactive effects of valsartan and genotype). Responder rates also differed between the genotypes: 72.8% in CC versus 58.0% in CT/TT (P = 0.03). Univariate analysis indicated a significant association of response to valsartan with blood pressure, diabetes, plasma aldosterone concentration, and CC homozygotes of REN C-5312T. Finally, multiple logistic regression analysis revealed that systolic blood pressure, CC homozygotes of REN C-5312T, and diabetes were independent predictors for responders with odds ratios (95% CI) of 2.49 (1.41–4.42), 2.03 (1.10–3.74), and 0.48 (0.24–0.96), respectively. CONCLUSIONS: This study provides strong support that a genetic variant of REN C-5312T and diabetes contribute to the effects of ARBs and are independent predictors for responder. Thus, in treatment of hypertension with ARBs, a new possibility for personalized medicine has been shown. |
format | Text |
id | pubmed-2713645 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-27136452010-08-01 Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers Konoshita, Tadashi Kato, Norihiro Fuchs, Sébastien Mizuno, Shinichi Aoyama, Chikako Motomura, Makoto Makino, Yasukazu Wakahara, Shigeyuki Inoki, Isao Miyamori, Isamu Pinet, Florence Diabetes Care Original Research OBJECTIVE: Recent studies have proven the favorable effects of angiotensin receptor blockers (ARBs) on cardiovascular and renal disorders. However, determinants of the response to ARBs remain unclear. We substantiated the hypothesis that genetic variants of the renin-angiotensin system (RAS) have significant impacts on the response to ARBs. RESEARCH DESIGN AND METHODS: Subjects comprised 231 consecutively enrolled hypertensive individuals including 45 type 2 diabetic subjects. Five genetic variants of the RAS, i.e., renin (REN) C-5312T, ACE insertion/deletion, angiotensinogen M235T, angiotensin II type 1 receptor A1166C, and angiotensin II type 2 receptor C3123A were assayed by PCR and restriction fragment-length polymorphism. A dose of 40–160 mg/day of valsartan was administered for 3 months as a monotherapy. RESULTS: Changes in diastolic blood pressure significantly differed between genotypes of REN C-5312T: 10.7-mmHg reduction (from 95.9 ± 12.9 to 85.2 ± 11.4) in CC versus 7.0-mmHg reduction (from 94.7 ± 14.0 to 87.7 ± 12.6) in CT/TT (P = 0.02 for interactive effects of valsartan and genotype). Responder rates also differed between the genotypes: 72.8% in CC versus 58.0% in CT/TT (P = 0.03). Univariate analysis indicated a significant association of response to valsartan with blood pressure, diabetes, plasma aldosterone concentration, and CC homozygotes of REN C-5312T. Finally, multiple logistic regression analysis revealed that systolic blood pressure, CC homozygotes of REN C-5312T, and diabetes were independent predictors for responders with odds ratios (95% CI) of 2.49 (1.41–4.42), 2.03 (1.10–3.74), and 0.48 (0.24–0.96), respectively. CONCLUSIONS: This study provides strong support that a genetic variant of REN C-5312T and diabetes contribute to the effects of ARBs and are independent predictors for responder. Thus, in treatment of hypertension with ARBs, a new possibility for personalized medicine has been shown. American Diabetes Association 2009-08 2009-06-09 /pmc/articles/PMC2713645/ /pubmed/19509012 http://dx.doi.org/10.2337/dc09-0348 Text en © 2009 by the American Diabetes Association. https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ (https://creativecommons.org/licenses/by-nc-nd/3.0/) for details. |
spellingShingle | Original Research Konoshita, Tadashi Kato, Norihiro Fuchs, Sébastien Mizuno, Shinichi Aoyama, Chikako Motomura, Makoto Makino, Yasukazu Wakahara, Shigeyuki Inoki, Isao Miyamori, Isamu Pinet, Florence Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers |
title | Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers |
title_full | Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers |
title_fullStr | Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers |
title_full_unstemmed | Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers |
title_short | Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers |
title_sort | genetic variant of the renin-angiotensin system and diabetes influences blood pressure response to angiotensin receptor blockers |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713645/ https://www.ncbi.nlm.nih.gov/pubmed/19509012 http://dx.doi.org/10.2337/dc09-0348 |
work_keys_str_mv | AT konoshitatadashi geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers AT katonorihiro geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers AT fuchssebastien geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers AT mizunoshinichi geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers AT aoyamachikako geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers AT motomuramakoto geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers AT makinoyasukazu geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers AT wakaharashigeyuki geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers AT inokiisao geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers AT miyamoriisamu geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers AT pinetflorence geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers AT geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers |